TET Systems and Novo Nordisk sign license agreement
|| Print ||
|Friday, 13 November 2009 10:00 (UTC + 1)|
Heidelberg, Germany, November 13 2003 /b3c newswire / - TET Systems Holding GmbH & Co. KG (“TET Systems”), a worldwide leader in controlled gene expression, today announced that TET Systems and Novo Nordisk A/S have signed a license agreement allowing the Hagedorn Research Institute (HRI), a research institute within Novo Nordisk A/S, the use of the Tet Technology for its internal research activities.
About TET Systems - www.tetsystems.com
TET Systems Holding is a privately held company located in Heidelberg, Germany. TET Systems Holding was founded by Prof. Dr. H. Bujard and colleagues based on their invention of the Tet Technology, the most widely used method to control gene expression in higher organisms. TET Systems Holding owns a broad patent portfolio covering the technology organized in six patent families comprising 31 granted patents and 14 patent applications. TET Systems markets licenses to the Tet Technology through its subsidiary IP Merchandisers. To date, more than 150 organizations have licensed the Tet Technology including academic institutions and research foundations. The largest group of licensees are pharmaceutical and biotech companies, with 17 of the top 20 BIG Pharma (2006) being Tet Technology licensees.